Company: GANX
Filing Date: 2025-04-17
Form Type: PRE 14A
Source: 0001558370-25-004958
Chunk: 45

Company: Gain Therapeutics, Inc.
Filing Date: 2025-04-17
Form: PRE 14A
Chunk 45
---
 a target of 35% of his annual base salary.

As a material inducement to Mr. Mack to enter into the Mack CFO Employment Agreement, the Board also approved the grant to Mr. Mack of an inducement equity award consisting of an option to purchase up to 200,000 shares of our common stock at an exercise price of $3.56 per share pursuant to our 2021 Inducement Equity Incentive Plan (the “Inducement Plan”), vesting over a four year period, with 25% vesting on the first anniversary thereof and the balance vesting in equal monthly installments over the remainder of the vesting period.

In the event of termination of Mr. Mack’s employment as Chief Financial Officer by us without cause, by Mr. Mack for good reason or Mr. Mack’s employment terminated upon his death or disability, in all cases subject to Mr. Mack entering into and not revoking a separation agreement in a form acceptable to us, he would have been eligible to receive cash severance equal to six (6) months of base salary. In addition, if Mr. Mack timely elected to receive continued coverage under the Company’s group health care plan pursuant to COBRA or applicable state continuation coverage laws, then he would have been eligible to receive payment of the employer portion of his COBRA premiums for the six (6) month period after the termination of employment occurred.

If such termination occurred on the date of a change of control or within twelve (12) months thereafter, then as additional components of severance, Mr. Mack would have been eligible to receive (x) (i) a cash severance equal to twelve (12) months of base salary; (ii) if Mr. Mack timely elected to receive continued coverage under our group health care plan pursuant to COBRA or applicable state continuation coverage laws, then he would have been eligible to receive payment of the employer portion of his COBRA premiums for the twelve (12) month period after the termination; (iii) an annual cash bonus equal to his pro-rated annual target bonus opportunity for the year in which the termination of employment occurred, and (iv) an annual cash bonus equal to his annual target bonus opportunity that would have accrued during the twelve (12) month period after the termination of employment occurs; and (y) accelerated vesting of 100% of any then-unvested stock awards.

#### Gianluca Fuggetta
In connection with his appointment as our Principal Financial Officer, we entered